Dr. Reddy's Launches Generic Semaglutide Injection in Canada, Marking G7 Milestone
Dr. Reddy's Laboratories Ltd. announced the launch of its generic Semaglutide Injection in Canada on May 15, 2026. The launch follows the company's receipt of the Notice of Compliance (NOC) from Health Canada on April 28, 2026, positioning Dr. Reddy's as a key provider of advanced diabetes care in the Canadian market.Dr. Reddy's is noted as the first company to achieve Health Canada approval for generic Semaglutide Injection in Canada, making Canada the first G7 country to grant market authorization for the drug. This development underscores the company's readiness to ensure patient access following regulatory approval.
The Semaglutide Injection in Canada is indicated for the once-weekly treatment of adults with type 2 diabetes mellitus. The medication aims to improve glycemic control when used in combination with diet and exercise.
The product is supplied as a sterile solution for subcutaneous injection in a pre-filled pen. It is available in two strengths: 2 mg/pen and 4 mg/pen. Both strengths deliver Semaglutide at a concentration of 1.34 mg/ml. Specifically, the 2 mg/pen is designed to deliver 0.25 mg or 0.5 mg doses, while the 4 mg/pen delivers 1 mg doses per injection.
Erez Israeli, Chief Executive Officer of Dr. Reddy's, stated, "We are pleased to launch our generic Semaglutide Injection in Canada, within days of receiving Health Canada approval. The milestone highlights our readiness to serve the Canadian patients, supported by our deep expertise in complex drug and peptide development. With a well-established presence and strong market access capabilities in Canada, we remain committed to bringing advanced, high-quality, and affordable GLP-1 therapies closer to patients. The Canada launch builds on the momentum of our recent launch in India under the brand name Obeda®. As GLP-1 therapies continue to be a key focus area for us, we are actively working to expand access across multiple global markets."
The treatment regimen for Semaglutide Injection includes use in combination with diet and exercise for various scenarios of type 2 diabetes management, including when metformin is inappropriate, or when maximizing control requires combination with sulfonylurea or sodium-glucose cotransporter 2 inhibitor (SGLT2i).
Semaglutide has not been studied in combination with prandial insulin (short acting). The company clarified that Semaglutide Injection is not a substitute for insulin and should not be used in patients with type 1 diabetes mellitus or for the treatment of diabetic ketoacidosis.
DRREDDY Stock Price Movement
On Friday, shares of Dr. Reddy's Laboratories Limited edged higher, rallying by 3.04% to close at ₹1336.7. The stock saw significant trading volume, with shares gaining ₹39.60 apiece amid a substantial flow of 3.98 million shares.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.